Home › Funds › BRAIDWELL LP › SYRE
BRAIDWELL LP position in SYRE
SPYRE THERAPEUTICS INC · Health Care
BRAIDWELL LP reported holding 879,467 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$78.1M, representing 3.07% of its reported portfolio and ranking #5 among its reported holdings. BRAIDWELL LP has disclosed SYRE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's SYRE position evolved
BRAIDWELL LP first disclosed a stake in SYRE in Q4 2023 at 515,000 shares (US$11.1M). The position peaked in Q2 2026 at 879,467 shares, worth US$78.1M. Across 11 filings, BRAIDWELL LP increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 879,467 shares valued at US$78.1M — a reduction of -53,356 shares quarter over quarter.. Notable position changes include a 388% increase in Q2 2024 (shares were roughly flat over the following quarter), a 37% trim in Q4 2025 (shares rose 54% over the following quarter), a 43% trim in Q1 2026 (shares rose 76% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 515.00K | $11.08M | New |
| Q1 2024 | 515.00K | $19.53M | Hold |
| Q2 2024 | 2.51M | $59.12M | Add |
| Q3 2024 | 2.19M | $64.40M | Reduce |
| Q4 2024 | 2.58M | $60.03M | Add |
| Q1 2025 | 2.58M | $41.60M | Hold |
| Q2 2025 | 2.58M | $38.60M | Hold |
| Q3 2025 | 2.58M | $43.21M | Hold |
| Q4 2025 | 1.63M | $53.55M | Reduce |
| Q1 2026 | 932.82K | $47.05M | Reduce |
| Q2 2026 | 879.47K | $78.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M sh · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- Siren, L.L.C. 968.60K sh · $85.99M · Q2 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
- EMERALD ADVISERS, LLC 567.43K sh · $50.38M · Q2 2026
More on BRAIDWELL LP
FAQ
How long has BRAIDWELL LP held SYRE?
BRAIDWELL LP has disclosed SYRE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is BRAIDWELL LP's current position in SYRE?
As of Q2 2026, BRAIDWELL LP holds 879.47K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $78.08M, representing 3.07% of its reported portfolio and ranking #5.
Has BRAIDWELL LP been buying or selling SYRE?
In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in SYRE. The position peaked in Q2 2026 at 879.47K shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.